Stephanie Lim

Medical oncologist @SWSLHD; cancer researcher @inghaminstitute @westernsydneyu; mum of three; visual & culinary arts enthusiast. Views are my own.

[Dr Travis Brown 🎧 @DrTravisBrown]

This Medical Life podcast

New episode out now: Episode 73 Colorectal Cancer (Part 3) | Management

Our guests include Dr Stephanie Lim (Oncologist), Dr Meredith Johnston (Radiation Oncologist) and Dr Emilia Ip (Genetist)

Available on all podcasting services & Spotify

[ONJ Cancer Research Institute @ONJCRI]

🎉 Thrilled to share that an @ONJCRI and @latrobe led project has been awarded $5 million from the @nhmrc, to investigate treatment resistance in colorectal cancer. Congratulations to Prof John Mariadason, Dr Lisa Mielke and collaborators!

Read more 👉 https://t.co/9sbru45oxI

[Stephanie Lim @StephHLim]

The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer https://t.co/IbpAqLyXEU @IJMS_MDPI
👉CDX2 is prognostic in CRC
👉larger studies required to confirm predictive utility in left-sided & rectal cancers
@DrTaraLRoberts @westernsydneyu @InghamInstitute @SWSLHD

[Gibbs Lab @gibbs_lab]

Dr Vanessa Wong and team had their abstract published as part of the 2024 ASCO Annual meeting this week in Chicago 🌟

🔍 A high proportion of Australian patients with metastatic colorectal cancer undergo testing for genetic mutations (mismatch repair testing).

[Stephanie Lim @StephHLim]

A privilege to chat with Dr Lidia Schapira @StanfordMed for JCO Cancer Stories podcast @JCOGO_ASCO @SWSLHD
And a lovely way to end #ASCO2024 which focused on ‘The art and science of cancer care - from comfort to cure’
https://t.co/lYxMYlDxwK
#ArtOfOncology

[Arndt Vogel @ArndtVogel]

🔥off the press: An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
@ESMO_Open
👉Median follow-up 45.4 mo
👉ORR 37.0%
👉mDOR 9.1 mo
👉mPFS 7 mo
👉mOS 17.5 m
👇my personal author share link:
https://t.co/G8aLxkQ1do
@myESMO @EASLnews @ILCAnews @curecc #livertwitter

[Stephanie Lim @StephHLim]

“Biology continues to be the king, and selection the queen” — David Chang discussing old tools and new tricks in pancreas cancer #ASCO2024 #crcsm

[Arndt Vogel @ArndtVogel]

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer #ASCO24
👉100% cCR, no relapse & no additional therapy
👉20 pts with sustained response of 12mo
👉ctDNA as an early marker of response
🧐Just amazing efficacy…
@myESMO

[Krishan Jethwa @KrishanJethwa]

And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪

✅100% cCR rate
✅0 Local or distance relapses
✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m

THIS. IS. AWESOME

#ASCO24

[Stephanie Lim @StephHLim]

ESOPEC
👉Median OS 66 m FLOT vs 37 m CROSS
👉pCR 17% FLOT vs 10% CROSS

🤔How would adj nivo change results?
🤔I would pick FLOT over CROSS, but maybe I can have both?
🤔Perhaps best outcome: Chemotherapy -> CRT -> surgery -> adj IO
Not end of story.
#ASCO2024 #crcsm @OncoAlert

[Stephanie Lim @StephHLim]

NEOPRISM-CRC & IBI310
👉Starting to shift landscape for neoadjuvant treatment for MSI-H/ dMMR colon cancer
Raises so many questions:
🤔Can we avoid surgery?
🤔Is pCR surrogate for cure?
🤔Choice and length of IO?
#ASCO2024 #crcsm @OncoAlert

[Stephanie Lim @StephHLim]

CHECKMATE 8HW
👉excited about option of nivo/ipi as 1L SOC for MSI-H/ dMMR mCRC
👉24 month PFS2 -> 83%
👉but how does it compare to KEYNOTE 177 pembro?
👉excitedly awaiting the nivo arm
#ASCO2024 #crcsm @OncoAlert

[Nature Medicine @NatureMedicine]

Now at #ASCO24: In the phase 3 FRUTIGA trial, the multi anti-VEGFR inhibitor #fruquintinib + chemotherapy significantly extended progression-free survival, but not overall survival, as 2L therapy in patients with advanced #GastricCancer or #GEJCancer https://t.co/i64ljYnQ4N

[Stephanie Lim @StephHLim]

I have no questions to ask 😆

[gilberto lopes @GlopesMd]

Alright! It’s that time of the year again. #ASCO24 is about to start. Here are our now classic rules of engagement. (Still don’t know the author to quote and credit). As usual @VoglNY is exempt. @asco @oncoalert @n8pennell @NarjustFlorezMD @Latinamd @DrSGraff @cancermd @mtmdphd @oncology_bg @GlopesMd @SylvesterCancer @JTrentMDPhD #trentselfie @EmilyJonczak @CharuAggarwalMD @montypal @DrChoueiri @ADesaiMD @neerajaiims @OphiraG @COlazagasti @SamuelKareffMD @OncoAlert

[Mark Lewis, MD, FASCO @marklewismd]

New conference, same old game
#ASCO24

[Stephanie Lim @StephHLim]

Oh hello Chicago! Haven’t seen you in a while. #ASCO2024

[Stephanie Lim @StephHLim]

When CALD patients say no thanks to treatment.
The Road Less Traveled: Perspective From an Australian Oncologist | JCO Global Oncology https://t.co/wSRHwSgOvY
#JCOGO
@JCOGO_ASCO @SWSLHD

[Dr Deme Karikios @DKarikios]

Lovely work from @shalsubra

Patients' perception of the benefits of palliative systemic therapy for advanced cancer - Subramaniam - 2024 - Internal Medicine Journal - Wiley Online Library https://t.co/gHmXj4UxFa

@BelindaKiely @martinst

[JMIRO Journal @JMIRO_Journal]

📢From our current issue: gaps in diversity amongst investigators in TROG clinical trials

👉Only 1 in 5 trials led by female principal investigators
👉Only 1 in 3 trials led by female chief investigators

https://t.co/3lTIQp4vZ8

[Stephanie Lim @StephHLim]

So relatable.

[JAMA Network Open @JAMANetworkOpen]

Women and parents report greater burden from early AM/late PM multi-disciplinary tumor boards. Radiologists, pathologists, those with ≥2 kids, or attending ≥3 hrs/wk of tumor boards report greater overall burden. https://t.co/GkzFJ3e1qx @_katelynatkins @CedarsSinai